专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070202099A1 Antibody Drug 审中-公开
标题翻译：抗体药物
公开(公告)号：US20070202099A1
公开(公告)日：2007-08-30
申请号：US10594773
申请日：2005-03-29
申请人： Hiroshi Inooka , Nobuhiro Suzuki , Toshiro Kokubo , Tomofumi Kurokawa
发明人： Hiroshi Inooka , Nobuhiro Suzuki , Toshiro Kokubo , Tomofumi Kurokawa
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K47/6843
摘要： The present invention provides an agent for improving the blood stability of an endogenous ligand, which comprises an antibody that has affinity to the mammalian endogenous ligand but substantially does not neutralize the same, and the above-described agent for the prophylaxis and/or treatment for a disease for which an increase in the blood concentration of the endogenous ligand and/or an prolonged blood half-life is prophylactically or therapeutically effective. Provided that the above-described agent is administered alone to a mammal without co-administering the same or substantially the same compound as the endogenous ligand, the blood stability of the endogenous ligand increases and the receptor activity-regulatory action thereof is enhanced.
摘要翻译：本发明提供了一种用于改善内源性配体的血液稳定性的试剂，其包含对哺乳动物内源性配体具有亲和力但基本上不中和其的抗体，以及上述用于预防和/或治疗内源性配体的血液浓度的增加和/或延长的血液半衰期的预防或治疗有效的疾病。假设将上述药剂单独施用于哺乳动物而不与内源性配体相同或基本相同的化合物共同施用，则内源性配体的血液稳定性增加，并且其受体活性调节作用增强。

2. 发明授权

US6117455A Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent 失效
标题翻译：无定形水溶性药物活性剂的缓释微胶囊
公开(公告)号：US6117455A
公开(公告)日：2000-09-12
申请号：US535386
申请日：1995-09-28
申请人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
发明人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
IPC分类号： A61K9/16 , A61K9/52 , A61K9/50 , A61F2/00 , A61F9/02 , A61F13/00
CPC分类号： A61K9/1647 , A61K9/1611 , A61K9/1617 , A61K9/1623 , Y10S977/775 , Y10S977/788 , Y10S977/801 , Y10S977/906 , Y10S977/915
摘要： A sustained-release microcapsule contains an amorphous water-soluble pharmaceutical agent having a particle size of from 1 nm-10 .mu.m and a polymer. The microcapsule is produced by dispersing, in an aqueous phase, a dispersion of from 0.001-90% (w/w) of an amorphous water-soluble pharmaceutical agent in a solution of a polymer having a wt. avg. molecular weight of 2,000-800,000 in an organic solvent to prepare an s/o/w emulsion and subjecting the emulsion to in-water drying.
摘要翻译：缓释微胶囊含有粒度为1nm-10μm的无定形水溶性药剂和聚合物。该微胶囊是通过在水相中分散0.001-90％（w / w）的无定形水溶性药剂的分散体制成的。平均在有机溶剂中分子量为2,000-800,000，以制备s / o / w乳液，并对乳液进行水中干燥。

3. 发明申请

US20090263840A1 Novel Monoclonal Anitbody and Use thereof 审中-公开
标题翻译：新型单克隆抗体及其用途
公开(公告)号：US20090263840A1
公开(公告)日：2009-10-22
申请号：US11992008
申请日：2006-09-14
申请人： Jun Hashimoto , Akihide Nampei , Wataru Ando , Tomofumi Kurokawa , Tsutomu Oshima
发明人： Jun Hashimoto , Akihide Nampei , Wataru Ando , Tomofumi Kurokawa , Tsutomu Oshima
IPC分类号： G01N33/53 , C07K16/00
CPC分类号： C07K16/18 , C07K2317/34 , G01N33/6887 , G01N2800/10 , G01N2800/108
摘要： The present invention provides an antibody capable of specifically recognizing the same amino acid sequence as an antigenic determinant of mouse monoclonal antibody MAB-ME-16F4.3 (FERM BP-10329), and an antibody of capable of specifically recognizing the same amino acid sequence as an antigenic determinant of mouse monoclonal antibody MAB-ME-12C9.2 (FERM BP-10328), and methods of risk prediction of bone fracture and/or diagnosis of osteoporosis by detecting a MEPE-derived molecule in a biological sample using the above-mentioned two kinds of antibodies.
摘要翻译：本发明提供能够特异性识别与小鼠单克隆抗体MAB-ME-16F4.3（FERM BP-10329）的抗原决定簇相同的氨基酸序列的抗体，以及能够特异性识别相同氨基酸序列的抗体作为小鼠单克隆抗体MAB-ME-12C9.2（FERM BP-10328）的抗原决定簇，以及通过使用上述检测生物样品中的MEPE衍生的分子检测骨折和/或骨质疏松症诊断的风险预测方法所述两种抗体。

4. 发明授权

US5506135A Hybrid monoclonal antibodies, their production and use 失效
标题翻译：混合单克隆抗体，其生产和使用
公开(公告)号：US5506135A
公开(公告)日：1996-04-09
申请号：US366366
申请日：1994-12-29
申请人： Susumu Iwasa , Tomofumi Kurokawa , Yukio Toyoda
发明人： Susumu Iwasa , Tomofumi Kurokawa , Yukio Toyoda
IPC分类号： A61K38/00 , A61K38/46 , A61K39/395 , A61K45/00 , A61K47/48 , C07K16/46 , C12N5/10 , C12N15/02 , C12P21/08 , C12R1/91 , C12N5/18 , C07K16/36 , C07K16/40
CPC分类号： C07K16/468 , A61K47/4843 , A61K47/48676 , A61K38/00
摘要： The present invention provides a hybrid monoclonal antibody having specificities against fibrin and thrombolytic substance, a polydoma which produces said antibody and thrombolytic agent comprising said antibody and thrombolytic substance which is immunologically coupled thereto, and methods of using said antibody in combination with thrombolytic substance for lysis or removal of thrombi.
摘要翻译：本发明提供了具有纤维蛋白和溶栓物质特异性的杂交单克隆抗体，产生所述抗体的多核苷酸和包含所述抗体的血栓溶解剂和与其免疫相结合的溶栓物质，以及将所述抗体与溶栓物质组合使用的方法或去除血栓。

5. 发明申请

US20100008928A1 AGENT FOR PREVENTING/TREATING CANCER 审中-公开
标题翻译：用于预防/治疗癌症的药剂
公开(公告)号：US20100008928A1
公开(公告)日：2010-01-14
申请号：US12444382
申请日：2007-10-04
申请人： Shuji Sato , Tsutomu Oshima , Tomofumi Kurokawa
发明人： Shuji Sato , Tsutomu Oshima , Tomofumi Kurokawa
IPC分类号： A61K39/395 , C07K16/30 , C12N5/00
CPC分类号： C07K14/70503 , A61K2039/505 , C07K16/2803 , C07K16/30 , C07K16/3069 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2319/30
摘要： A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.
摘要翻译：针对包含与SEQ ID NO：1或SEQ ID NO：3所示的氨基酸序列相同或基本相同的氨基酸序列的蛋白质的人单克隆抗体，其部分肽或其盐可用作试剂用于预防/治疗癌症等，癌细胞的细胞凋亡诱导剂，癌细胞的生长抑制剂，通过抗体的Fc区介导的宿主防御机制的抗癌细胞的细胞毒性剂等。

6. 发明申请

US20090142346A1 Preventive/Remedy for Cancer 审中-公开
标题翻译：预防/治疗癌症
公开(公告)号：US20090142346A1
公开(公告)日：2009-06-04
申请号：US11992966
申请日：2006-10-06
申请人： Shuji Sato , Tsutomu Oshima , Tomofumi Kurokawa
发明人： Shuji Sato , Tsutomu Oshima , Tomofumi Kurokawa
IPC分类号： A61K39/395 , C07K16/18 , C12N5/06
CPC分类号： C07K14/70596 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/2803 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2319/30 , G01N33/574 , G01N33/57407
摘要： A human monoclonal antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 3, its partial peptide, or a salt thereof, is useful as an agent for preventing/treating cancer, etc., an apoptosis inducer of cancer cells, a growth inhibitor of cancer cells, a cytotoxic agent against cancer cells through a host defense mechanism mediated by the Fc region of an antibody, and so on.
摘要翻译：针对包含与SEQ ID NO：1或SEQ ID NO：3所示的氨基酸序列相同或基本相同的氨基酸序列的蛋白质的人单克隆抗体，其部分肽或其盐可用作试剂用于预防/治疗癌症等，癌细胞的细胞凋亡诱导剂，癌细胞的生长抑制剂，通过抗体的Fc区介导的宿主防御机制的抗癌细胞的细胞毒性剂等。

7. 发明授权

US06190702B1 Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase 失效
标题翻译：通过将冻干的多肽分散在油相中制备的缓释材料
公开(公告)号：US06190702B1
公开(公告)日：2001-02-20
申请号：US08849172
申请日：1997-05-30
申请人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
发明人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
IPC分类号： A61K950
CPC分类号： A61K9/1647 , A61K9/1694 , Y10S514/963 , Y10S514/964
摘要： A sustained-release preparation containing a bioactive polypeptide is prepared using a starting material containing a lyophilized product of an aqueous solution or suspension of the bioactive polypeptide in a non-ionic surfactant. The lyophilized product is dispersed in an oil phase, which further contains a biocompatible, biodegradable polymer.
摘要翻译：使用含有生物活性多肽的水溶液或悬浮液的冻干产物的起始材料在非离子表面活性剂中制备含有生物活性多肽的持续释放制剂。冻干产物分散在油相中，该油相还含有生物相容的可生物降解的聚合物。

8. 发明授权

US5876756A Microcapsule containing amorphous water-soluble 2-piperazinone-1-acetic acid compound 失效
标题翻译：含有无定形水溶性2-哌嗪酮-1-乙酸化合物的缓释微胶囊
公开(公告)号：US5876756A
公开(公告)日：1999-03-02
申请号：US724498
申请日：1996-09-30
申请人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
发明人： Shigeyuki Takada , Tomofumi Kurokawa , Susumu Iwasa
IPC分类号： A61K9/16 , A61K9/52 , A61K31/495
CPC分类号： A61K9/1647 , A61K31/495 , Y10S514/821 , Y10S514/822 , Y10S514/951 , Y10S514/963 , Y10S514/964 , Y10S977/906 , Y10S977/915 , Y10S977/92
摘要： A microcapsule contains a pharmaceutically effective amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof and a polymer binder and a method of preparing said microcapsule. The microcapsule is produced by dispersing in an aqueous phase a dispersion of the amorphous water-soluble 2-piperazinone-1-acetic acid compound or salt thereof in a solution of a polymer in an organic solvent to give an s/o/w type emulsion and subjecting the emulsion to in-water drying. The sustained-release microcapsule entraps 2-piperazinone-1-acetic acid compound or the salt thereof, as a drug, in high concentration, and in reducing the initial release of the drug, thereby reducing undesirable side effects of the drug.
摘要翻译：微胶囊含有药学有效的无定形水溶性2-哌嗪酮-1-乙酸化合物或其盐和聚合物粘合剂以及制备所述微胶囊的方法。微胶囊是通过在水相中将无定形水溶性2-哌嗪酮-1-乙酸化合物或其盐的分散体分散在聚合物在有机溶剂中的溶液中制得的，得到s / o / w型乳液并对乳液进行水中干燥。缓释微胶囊以高浓度捕获2-哌嗪酮-1-乙酸化合物或其盐作为药物，并减少药物的初始释放，从而减少药物的不良副作用。

9. 发明授权

US5496549A Bispecific monoclonal antibodies, thrombolytic agent and method of cell lysis 失效
标题翻译：双特异性单克隆抗体，溶栓剂和细胞裂解方法
公开(公告)号：US5496549A
公开(公告)日：1996-03-05
申请号：US350497
申请日：1994-12-06
申请人： Hiroh Yamazaki , Kenjiro Tanoue , Susumu Iwasa , Tomofumi Kurokawa
发明人： Hiroh Yamazaki , Kenjiro Tanoue , Susumu Iwasa , Tomofumi Kurokawa
IPC分类号： A61K38/00 , A61K47/48 , C07K16/28 , C07K16/40 , C07K16/46 , C12P21/08 , A61K51/00 , A61K38/49 , A61K51/10 , C07K16/38
CPC分类号： A61K47/48646 , A61K47/48669 , C07K16/28 , C07K16/40 , C07K16/468 , A61K38/00
摘要： Disclosed are a bispecific hybrid MoAb having specificity for both an activated platelet and a substance having thrombolytic activity, and a thrombolytic agent comprising the above bispecific MoAb and a substance having thrombolytic activity immunologically bound thereto, whereby efficient, rapid thrombolysis is possible.
摘要翻译：公开了对具有溶栓活性的活化血小板和物质具有特异性的双特异性杂交体MoAb，以及包含上述双特异性MoAb的溶血栓剂和具有免疫结合的溶栓活性的物质，由此能够进行有效的快速溶栓。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式